|
|
Post by agedhippie on May 1, 2022 11:13:13 GMT -5
Aged - I am not sure what you are smoking. When looking at afrezza for TIR you can only include the hours someone is awake. Afrezza has no affect when someone is sleeping. Thats the job of the basal. its also the beauty of afrezza - its in and out real fast. If you want to increase TIR during sleeping hours either take more basal or use a pump. Al use to say to use a simple patch pump. With afrezza there is no need for all the 780 complexity. However with the study just presented at ATTD with a single large dose of afrezza it seems they can bring the T1 safely down an additional 51 points which will bring the baseline down to carry them through the night. Combine the ATTD approach, apply the 51 points into the STAT results and afrezza kicks butt all over the 780 through the night. You have the same basal for both Afrezza and RAA so these should cancel each other. That is why Mannkind did not blame the basal. The TIR was awful, far worse than I think it should have been, and that's what people look at since that was the primary outcome measure of the study (the 1-4 hour period was a secondary outcome measure). They chose that measure because bolus insulin, like basal, is just one component and what matters is the whole interaction and not just a part in isolation. The poster study is old news. It replicates an earlier 2014 study ( www.clinicaltrials.gov/ct2/show/NCT00747006) and suffers from the same issues - standardized meals, population size, and duration. As is normal the replacement meal for the poster was a nutrition shake with almost no fat (4g) with the bulk being carbs - this is ideal for Afrezza since digestion will be fast. Now try a real meal with fats and fiber to slow digestion and you are going to need a second dose because digestion will not be that fast. Also the data was only collected for the first 2 hours so there is nothing on what happened after that, for all we know it may behave exactly as the STAT study did. This is why the trial description says it's just a PoC for a trial - it's not real world, it's about designing trial protocols. No proper trials, no change. It's simple. |
|
|
|
Post by sayhey24 on May 2, 2022 6:59:57 GMT -5
Aged - Come on Man! Now you are telling me afrezza and the RAA cancel each other out? They are very different. Afrezza is out of the system and gone. The RAA is still in the system and working 2+ hours after eating and maybe just kicking into high gear. Your original argument was about the 780 pump which is pumping RAA all night long. Afrezza is long gone before bed.
I am not sure what the 2014 study has to do with the new ATTD study. The ATTD study was to show the afrezza label is wrong in that it has people taking way too little afrezza. It was not about increasing carbs as the 2014 study was. The ATTD study is showing doubling the dose should handle the fats and fiber and afrezza will win. It may not be as good as second dosing but it looks pretty damn good. We do know in the Affinty-1 trial when the NC doctor did double dose he crushed the RAA arm. If we take the other Affinty-1 results and apply the 51 point reduction - WoW! Afrezza kicks butt all over the RAA. The thing is the real benefit with afrezza is the T2 space not the T1s but dose doubling seems to have significant T1 benefit.
Aged - you give one excuse after another for not trying it. Bill from VDex has offered to give a free trial. You can be the personal trial since you keep saying "No proper trial". Why not give it a personal trial? It's simple. Your excuse use to be lung damage and we know that's not an issue. VDex has had a lot of success. You won't be their first success.
BTW - The ATTD study also shows doubling the dose does not result in additional hypos - which surprised me a bit with the T1s since you never know how the basal is going the affect the liver. Harry posted this on another thread from the ATTD. An attendee had air bubbles in her pump tube and her BG rose to 300. Someone "Deepak" gave her some afrezza and boom - problem fixed. The thing is she nicely bottomed at 65 and started coming back up so her liver seems to have worked just like those in the ATTD study. "Seeing is Believing" - It would have been nice for her to have taken the afrezza on stage. I am hoping Mike does some of these demo's at ADA in June. Of course they won't be "proper trials" but we do have the kids trial and India trial underway.
|
|
|
|
Post by mango on May 5, 2022 11:50:00 GMT -5
Agree…. And of course it’s true ..like I’ve said before it’s not all about Insurance. This is why Vdex hires their own doctors, yes this is the way they think… why… there are so many reasons why, but personally I would not wanna be locked to a pump day in and day out! It should be very simple but it has to come from the patients. The doctors don’t want to take the time, they don’t get compensated for it. Bill has said this many times …he grew up in a family of doctors, and we deal with this daily, they have to be completely retrained. Look how long it took Ginger! But the good news is once somebody does take the time and if they’re high profile enough the word will get out. It’s picking up steam now. Ginger is a pretty big turning point for sure. Not long ago she knew nothing about Afrezza and was unknowingly writing articles with incorrect information on insulins. Now she’s an Afrezza User for life. |
|
|
|
Post by cedafuntennis on May 5, 2022 14:28:52 GMT -5
To share an experience I had at the gym the other day. I saw this young man, in excellent physical shape, take a break from his exercise to inject himself. So when in the sauna, I asked him if it was insulin and he said yes. So I asked him if he knew about Afrezza. He did not but interestingly enough, he knew of Mannkind. So after I explained and showed him the PK and so on, he asked his Endo as he already had an appointment with him. His Endo, who apparently is a researcher most of the time, knew all about Afrezza and did research on it when it first came out. He told him it was a very good product, very fast and efficient BUT he does not have any patients on it yet because all had hypos due to the glucose level dropping too fast and patients were not comfortable with it. He offered to put my friend on Afrezza to which he agreed, but now I am afraid for him as it looks like dosing may be an issue (told him to pay attention to that).
He is in the Orlando, FL area so there is no VDex here. Sports was super kind some time ago to offer her assistance with another friend, so I am wondering if that offer would extend to this young man as I would hate for him to go the wrong path at this point in time.
|
|
|
|
Post by porkini on May 5, 2022 14:47:29 GMT -5
To share an experience I had at the gym the other day. I saw this young man, in excellent physical shape, take a break from his exercise to inject himself. So when in the sauna, I asked him if it was insulin and he said yes. So I asked him if he knew about Afrezza. He did not but interestingly enough, he knew of Mannkind. So after I explained and showed him the PK and so on, he asked his Endo as he already had an appointment with him. His Endo, who apparently is a researcher most of the time, knew all about Afrezza and did research on it when it first came out. He told him it was a very good product, very fast and efficient BUT he does not have any patients on it yet because all had hypos due to the glucose level dropping too fast and patients were not comfortable with it. He offered to put my friend on Afrezza to which he agreed, but now I am afraid for him as it looks like dosing may be an issue (told him to pay attention to that). He is in the Orlando, FL area so there is no VDex here. Sports was super kind some time ago to offer her assistance with another friend, so I am wondering if that offer would extend to this young man as I would hate for him to go the wrong path at this point in time. |
|
|
|
Post by sportsrancho on May 5, 2022 17:39:35 GMT -5
Sure I will pass this along, and on another note Bill agrees with Joey, same type of experience, two years older, 2018 :-) “works as usual”
|
|
|
|
Post by sportsrancho on May 5, 2022 18:09:47 GMT -5
To share an experience I had at the gym the other day. I saw this young man, in excellent physical shape, take a break from his exercise to inject himself. So when in the sauna, I asked him if it was insulin and he said yes. So I asked him if he knew about Afrezza. He did not but interestingly enough, he knew of Mannkind. So after I explained and showed him the PK and so on, he asked his Endo as he already had an appointment with him. His Endo, who apparently is a researcher most of the time, knew all about Afrezza and did research on it when it first came out. He told him it was a very good product, very fast and efficient BUT he does not have any patients on it yet because all had hypos due to the glucose level dropping too fast and patients were not comfortable with it. He offered to put my friend on Afrezza to which he agreed, but now I am afraid for him as it looks like dosing may be an issue (told him to pay attention to that). He is in the Orlando, FL area so there is no VDex here. Sports was super kind some time ago to offer her assistance with another friend, so I am wondering if that offer would extend to this young man as I would hate for him to go the wrong path at this point in time. “We are happy to help him. At the outset let me say from the post it appears his endo, like most, really doesn’t understand Afrezza as well as he thinks he does. If so, he’d know the hypos he mentions really aren’t due to Afrezza. Likely those patients are Type 1 and on basal. It’s the basal that’s the problem. Regardless this is another example of what the marketing of Afrezza is up against.” ~Bill Just DM me and will try to set something up. |
|
|
|
Post by cedafuntennis on May 5, 2022 18:15:13 GMT -5
Thank you so much Bill. Sports, could you please email me at pmone12001.at.com the contact info and I will set it up. I don't have his phone number as we are all in the sauna in our bathing suits when we meet (TMI, I know) but I will take it as soon as I see him again. Most likely I will go there this evening for my daily swim.
|
|
|
|
Post by sportsrancho on May 5, 2022 19:55:40 GMT -5
That email wouldn’t go through but go ahead and have him call Claudia in New Mexico, and she will either take it herself or refer him to another one of our providers . +1 (575) 405-9453
|
|
|
|
Post by cedafuntennis on May 5, 2022 21:16:37 GMT -5
That email wouldn’t go through but go ahead and have him call Claudia in New Mexico, and she will either take it herself or refer him to another one of our providers . +1 (575) 405-9453 of course it didn't go through. Looks like my email got changed at posting to something totally weird. It is x@y.z. I just gave him Bill's response and Claudia's number. Thanks. He was very excited and makes me so happy to be able to help someone through you good people. Thank you and God Bless you all. |
|
|
|
Post by agedhippie on May 11, 2022 18:59:24 GMT -5
Aged - Come on Man! Now you are telling me afrezza and the RAA cancel each other out? They are very different. Afrezza is out of the system and gone. The RAA is still in the system and working 2+ hours after eating and maybe just kicking into high gear. Your original argument was about the 780 pump which is pumping RAA all night long. Afrezza is long gone before bed. If I did it wasn't what I meant. Rather that in STAT-1 both arms used the same basal so they should have been equally impacted. |
|
|
|
Post by agedhippie on May 11, 2022 19:03:48 GMT -5
“We are happy to help him. At the outset let me say from the post it appears his endo, like most, really doesn’t understand Afrezza as well as he thinks he does. If so, he’d know the hypos he mentions really aren’t due to Afrezza. Likely those patients are Type 1 and on basal. It’s the basal that’s the problem. Regardless this is another example of what the marketing of Afrezza is up against.” ~Bill Basal is a very common problem. People tend to partially use basal to cover meals and so take more than they should. Typically this gets uncovered when they move to a pump and the basal testing to set the profiles shows that they are overdosing basal - people almost always wind up on a lower basal rate. |
|
|
|
Reality
May 12, 2022 8:38:35 GMT -5
via mobile
Post by cedafuntennis on May 12, 2022 8:38:35 GMT -5
“We are happy to help him. At the outset let me say from the post it appears his endo, like most, really doesn’t understand Afrezza as well as he thinks he does. If so, he’d know the hypos he mentions really aren’t due to Afrezza. Likely those patients are Type 1 and on basal. It’s the basal that’s the problem. Regardless this is another example of what the marketing of Afrezza is up against.” ~Bill Basal is a very common problem. People tend to partially use basal to cover meals and so take more than they should. Typically this gets uncovered when they move to a pump and the basal testing to set the profiles shows that they are overdosing basal - people almost always wind up on a lower basal rate. interesting that someone put in his mind the risk of lung cancer... Of course i pointed out there have been no cases reported but of anyone has something more concrete to dispel this bad rumor, please let him know. Just another example of what Afrezza is encountering out there. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2022 12:19:54 GMT -5
Basal is a very common problem. People tend to partially use basal to cover meals and so take more than they should. Typically this gets uncovered when they move to a pump and the basal testing to set the profiles shows that they are overdosing basal - people almost always wind up on a lower basal rate. interesting that someone put in his mind the risk of lung cancer... Of course i pointed out there have been no cases reported but of anyone has something more concrete to dispel this bad rumor, please let him know. Just another example of what Afrezza is encountering out there. AFREZZA = Human Insulin + WATER + Inert molecule. I doubt there will be evidence of lung cancer. |
|
|
|
Post by Clement on May 12, 2022 13:00:30 GMT -5
Basal is a very common problem. People tend to partially use basal to cover meals and so take more than they should. Typically this gets uncovered when they move to a pump and the basal testing to set the profiles shows that they are overdosing basal - people almost always wind up on a lower basal rate. interesting that someone put in his mind the risk of lung cancer... Of course i pointed out there have been no cases reported but of anyone has something more concrete to dispel this bad rumor, please let him know. Just another example of what Afrezza is encountering out there. Pfizer -- Exubera -- lung cancer. Different company and different drug. Some docs live in the past. No lung cancer with Afrezza. www.reuters.com/article/us-pfizer-nektar/pfizer-warns-of-lung-cancer-with-inhaled-insulin-idUSWNAS722620080409 |
|
